TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower NRF2 levels in oligodendrocytes—cells that maintain the brain’s myelin—with greater cognitive decline in older adults. Mouse experiments suggest reducing NRF2 in these cells can cause myelin abnormalities, nerve-fiber loss and weaker cognitive improvement, but whether NRF2-targeting drugs can help people with age-related decline remains unknown.
Researchers studying older adults and mice have linked dysfunction in oligodendrocytes, the brain cells that maintain protective myelin around nerve fibers, with faster cognitive decline. The study, published in Nature Medicine, points to reduced activity of the protective protein NRF2 as a possible contributor, while leaving open whether treatments aimed at the pathway can preserve cognition in people.
The research, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, drew on the Lothian Birth Cohort 1936. Participants’ thinking skills had been tracked from childhood, giving researchers a long-term record to compare with later-life brain changes. Between ages 70 and 82, participants were assessed on memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional cognitive testing after age 70.
Most participants experienced some decline, but the pace differed. In brain tissue examined after participants died, greater decline was associated with fewer large nerve fibers and an abnormal buildup of myelin. Myelin normally insulates nerve fibers and helps signals travel efficiently. The researchers reported that these tissue changes were associated with the rate of decline, rather than simply a person’s cognitive test performance at one age.
The team found lower levels of NRF2 in oligodendrocytes among people with more severe decline. In mice, researchers reduced NRF2 specifically in these cells. The animals developed excessive myelin, lost large nerve fibers and showed less improvement in cognitive performance as they aged. These experiments support a possible causal role for reduced NRF2 activity in the mice; they do not establish that the same process causes decline in humans.
A New Target in Aging Brain Research
The findings challenge the simple view that myelin-producing cells are always protective. If aging oligodendrocytes become less able to maintain myelin and nerve fibers, their dysfunction could be one part of the process behind declining memory and thinking skills. The study does not show that these cells are the sole cause, but it gives researchers a specific cellular pathway to investigate.
The possible treatment angle is relevant because NRF2 is already targeted by drugs used for other neurological conditions, including multiple sclerosis. The researchers say that this creates a route for future investigation, not evidence that existing medicines prevent ordinary age-related cognitive decline. Any use for older adults would need to be tested for benefit and safety in that population.
As an affiliate, we earn on qualifying purchases.
Long-Term Cohort Meets Mouse Experiments
The human analysis used the Lothian Birth Cohort 1936, whose participants have been followed across much of their lives. That record enabled researchers to compare differences in cognitive change over time with brain tissue collected after death. The tissue findings are observational: they show an association between the measured brain features and decline, but cannot by themselves establish which came first.
The mouse experiments added a separate line of evidence by changing NRF2 activity in oligodendrocytes and observing subsequent effects. Together, the human and animal results connect cellular protection, myelin and nerve-fiber health with cognitive aging. The source report says NRF2-targeting medicines have been used in other conditions and cites prior work on cognition in multiple sclerosis; those findings do not demonstrate effectiveness against age-related decline.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
As an affiliate, we earn on qualifying purchases.
Human Treatment Benefits Remain Unknown
The results do not establish that lower NRF2 activity causes cognitive decline in people. The human tissue analysis links the two, while the experimental evidence comes from mice in which researchers deliberately reduced NRF2 in oligodendrocytes. It is not yet clear whether the same chain of events drives decline in older adults, or how much it contributes alongside other age-related brain changes.
The study also does not show that an existing NRF2-targeting drug can prevent or reverse cognitive decline in older adults. The source report does not specify the drug, a clinical trial in this population, or evidence of an appropriate dose and safety profile for this purpose. The size and representativeness of the tissue subset are also not detailed in the supplied report.
cognitive decline support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
The next step is to determine whether the NRF2 pathway can be safely and effectively targeted in people experiencing age-related cognitive decline. Further research would need to test whether treatment changes oligodendrocyte or myelin function and whether any such changes correspond to meaningful differences in memory or other thinking skills. The supplied report does not announce a clinical trial or provide a timeline for one.
Until human treatment studies provide evidence, the findings should be understood as identifying a potential research target, not a proven therapy. Researchers will also need to clarify how changes in NRF2, myelin and nerve fibers unfold over time in human aging.
As an affiliate, we earn on qualifying purchases.
Key Questions
What brain cells did the study examine?
It examined oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular defense and normal function. The researchers found lower levels of it in oligodendrocytes in people with greater cognitive decline.
Does the study prove that these cells cause cognitive decline in humans?
No. Human brain tissue showed an association, while experiments that reduced NRF2 and produced related changes were conducted in mice. The human findings do not prove cause and effect.
Can an existing drug prevent age-related cognitive decline?
The study does not establish that. NRF2-targeting drugs are used for other conditions, but whether they can help older adults with age-related cognitive decline requires testing.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
